Business Context and Reporting Period
Pasithea Therapeutics Corp. filed a Form 8-K reporting actions taken at the reconvened 2023 Annual Meeting of Stockholders on December 29, 2023. The filing was signed on January 2, 2024. The Company is incorporated in Delaware and its common stock and warrants trade on Nasdaq under KTTA and KTTAW, respectively.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
The Company reported that 20,836,623 shares of common stock were outstanding and entitled to vote, and 15,366,446 shares were represented at the reconvened meeting, constituting a quorum.
A previously announced one-for-twenty reverse stock split was confirmed to remain effective at 12:01 a.m. on January 2, 2024. The related corrective filings were made so the split would be effected as an amendment to the Second Amended and Restated Certificate of Incorporation.
Material Changes
- Stockholders approved and the Company filed a Second Amended and Restated Certificate of Incorporation, effective December 29, 2023.
- The Board was divided into three classes with staggered three-year terms, and director removal was limited to cause. Dr. Emer Leahy was designated Class I; Simon Dumesnil and Alfred Novak Class II; and Dr. Tiago Reis Marques and Prof. Lawrence Steinman Class III.
- Stockholders were prohibited from taking action by written consent without a meeting.
- Stockholder amendments to the bylaws now require approval by holders of at least 66 2/3% of the outstanding common stock.
- The certificate includes provisions addressing preferred-stock-related director appointments, Board committees, certain changes to authorized shares, and officer exculpation as permitted by Delaware law.
- The Board adopted Second Amended and Restated Bylaws, including an exclusive Delaware forum provision, revised advance-notice and director-nomination requirements, Rule 14a-19 compliance requirements, and clarified meeting and committee procedures.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The governance amendments may reduce stockholder ability to call special meetings, act by written consent, remove directors without cause, or amend the bylaws. The exclusive forum provision generally requires certain actions to be brought in Delaware state court or, if unavailable, the federal court for the District of Delaware.
The one-for-twenty reverse stock split is an unusual capital-structure event and may affect the number of shares outstanding, trading price, warrant terms, and other equity instruments; the filing text does not provide the resulting share count or detailed instrument adjustments.
Investor Verification Items
- Verify the effective implementation and post-split share count following the January 2, 2024 reverse stock split.
- Review the full Second Amended and Restated Certificate of Incorporation and Bylaws for the operative governance and litigation provisions.
- Assess the effects of the classified Board, for-cause removal standard, written-consent prohibition, and 66 2/3% bylaw-amendment threshold on stockholder rights.
- Confirm how the reverse split affects outstanding warrants and other equity-linked securities.
- Obtain separate financial filings for revenue, cash usage, liquidity, debt, operating performance, and going-concern information, none of which is provided in this Form 8-K.